Kimia is a drug discovery company applying high throughput precision chemistry in combination with genome editing and machine learning to identify druggable sites at key nodes of intervention in human disease. Kimia is building a next generation therapeutics discovery platform called ATLAS that combines AcTive Learning with Automated Synthesis and screening. ATLAS is powered by a highthroughput, nano-liter scale chemistry platform that provides Kimia with instant access to billions of drug-like compounds. Machine learning and computational chemistry are core components of ATLAS, utilizing chemical synthesis data and assay readouts to drive new compound design, synthesis, and screening in a continuous learning loop. Kimia is using ATLAS in combination with genome editing to interrogate biological pathways, uncover new targets, and to identify novel drugs for the treatment of cancer and immunological disorders.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.